Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 14.
- Outcome review added Archynetys revisited the signal after coverage cooled.
Source diversity sample: Yahoo Finance · Moomoo · FirstWord Pharma · Business Wire · BioWorld News · Intellectia AI · BioPharma Dive · Quiver Quantitative.
How this dossier is built: methodology · AI policy · corrections.
The reporting (15)
- CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever Yahoo Finance · 47d ago
- Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 Moomoo · 47d ago
- FDA staff report throws cold water on Capricor's DMD cell therapy bid FirstWord Pharma · 47d ago
- Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation Business Wire · 47d ago
- Adcom ‘cage match’ in store for Capricor? BioWorld News · 48d ago
- Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting Intellectia AI · 48d ago
- FDA scientists question Capricor data; Legend CEO steps down BioPharma Dive · 48d ago
- Capricor Therapeutics Provides Update Ahead of FDA Advisory Committee Meeting on Deramiocel BLA for Duchenne Muscular Dystrophy Quiver Quantitative · 48d ago
- How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story Yahoo Finance · 48d ago
- Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel simplywall.st · 48d ago
- FDA staff flags concerns for Capricor’s Duchenne heart disease therapy WTVB · 48d ago
- Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) MarketBeat · 48d ago
- FDA staff flags data concerns about Capricor's therapy; shares plunge Reuters · 48d ago
- Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait? Yahoo Finance · 48d ago
- Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug STAT · 48d ago
What happened
- Velocity & Diffusion: Coverage exploded across 13 distinct news outlets with 15 published articles, achieving a live velocity of 14.
- Primary Driver: Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
The FDA has raised questions about the efficacy and data of Capricor Therapeutics' drug intended to treat Duchenne heart disease. These concerns were raised ahead of a scheduled hearing.
Coverage from Reuters, STAT, and WTVB emphasizes the FDA staff's flags regarding the therapy, while Reuters notes a subsequent plunge in company shares. Yahoo Finance and MarketBeat report on the stock's current trading status, including a lease deal and a high volume of call options purchased by traders.
Attention now turns to the upcoming hearing to address the FDA's concerns. Coverage does not yet specify the date of the hearing or the exact nature of the data discrepancies.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 48d ago.
Questions people are asking
What did the FDA flag regarding Capricor's therapy?
FDA staff flagged concerns regarding the efficacy and data of the Duchenne heart disease therapy.
How did the market react to the FDA news?
According to Reuters, shares of Capricor Therapeutics plunged following the reports.
What other market activity is noted for CAPR?
MarketBeat reports that stock traders have purchased a large volume of call options on the company.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
From around our network
Related trends
There’s a New Outbreak Tied to Greens That You Should Know About, Says FDA
A sudden salmonella outbreak linked to broccoli sprouts has hospitalized patients and sparked nationwide recalls.
What to know about the new mRNA flu vaccine
The FDA’s September 8 approval of Moderna’s mRNA flu shot could reshape seasonal influenza protection.
The Newest COVID Shot Is Here — Doctors Suggest The Best Time To Get It For The Most Protection
Updated COVID‑19 shots arrive with doctors urging precise timing to lock in the season’s strongest protection.
FDA names acting heads of drug and vaccine centers to permanent roles
The FDA promotes its acting drug and vaccine chiefs to permanent posts, solidifying leadership for upcoming health initiatives.
A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
A first‑in‑class orexin agonist cleared global hurdles, promising a new wake‑up call for narcolepsy sufferers.
Dog supplements recalled over potential salmonella contamination
Dog supplements recalled over potential salmonella contamination
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.